204848-95-3

Upstream product

• 204849-20-7 C₁₅H₂₃LiSi 
• 204848-94-2 3,6,6-Trimethoxy-5-oxo-cyclohexa-1,3-dienecarboxylic acid ethyl ester 
• 204848-93-1 3-Hydroxy-2,5-dimethoxy-benzoic acid ethyl ester 
• 204849-21-8 3-bromo-2,5-dimethoxy-benzoic acid methyl ester 
• 204849-22-9 3-hydroxy-2,5-dimethoxybenzoic acid 

Downstream Products

• 204848-96-4 5-((Z)-Hex-3-ene-1,5-diynyl)-5-hydroxy-3,6,6-trimethoxy-cyclohexa-1,3-dienecarboxylic acid ethyl ester 
• 204848-99-7 5-((Z)-Hex-3-ene-1,5-diynyl)-3,6,6-trimethoxy-5-triethylsilanyloxy-cyclohexa-1,3-dienecarbaldehyde 
• 204848-98-6 [5-((Z)-Hex-3-ene-1,5-diynyl)-3,6,6-trimethoxy-5-triethylsilanyloxy-cyclohexa-1,3-dienyl]-methanol 
• 204848-97-5 5-((Z)-Hex-3-ene-1,5-diynyl)-3,6,6-trimethoxy-5-triethylsilanyloxy-cyclohexa-1,3-dienecarboxylic acid ethyl ester 

Relevant academic research and scientific papers

Synthesis of the antitumor agent aglycon (±)-calicheamicinone using an o-quinone monoketal strategy

Commercially available 5-methoxysalicylic acid 16 was converted into the o-quinone monoketal 21, which was attached to the enediyne 22, resulting in 23. After protection of the tert-alcohol 24 and conversion of the ester 25 to aldehyde 28, treatment with